Exciting Data on Atopic Dermatitis from EADV 2024

Professor April Armstrong highlights new advancements in atopic dermatitis treatments. Lebrikizumab proved safe and effective in older patients, while tralokinumab reduced symptoms in high-impact areas like the face. Promising new treatments, including OX40 inhibitors, are on the horizon. Additionally, topical JAK inhibitors like delgocitinib show similar efficacy to systemic therapies like dupilumab for chronic hand eczema.